Drug intelligence / Profile preview

methotrexate + methylprednisolone + prednisone

Development stage: Unknown
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral, Intravenous, Subcutaneous

Overview

A combination therapy consisting of methotrexate and corticosteroids (methylprednisolone and prednisone) used primarily for the treatment of inflammatory conditions such as rheumatoid arthritis and spinal cord injury. This combination has shown enhanced therapeutic benefits through complementary mechanisms of action, including better inhibition of inflammatory cytokines, enhanced antioxidant effects, and stronger anti-apoptotic properties. The combination may also reduce methotrexate-related side effects, allowing for higher tolerable doses and improved treatment outcomes.

Targets

GR (Glucocorticoid receptor)DHFR (Dihydrofolate reductase)

Beyond the preview

Go deeper on methotrexate + methylprednisolone + prednisone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on methotrexate + methylprednisolone + prednisone.

Explore the full profile